Menu
Close
Home
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Latest Development
Company News
Investor Relations
Information Disclosure
Presentations
Corporate Governance
Investor Calendar
IR Contact
Join Us
Contact Us
Global
CN
TC
Home
CN
TC
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Scientific News
Company News
Investor Relations
Information Disclosure
Corporate Governance
Investor Calendar
Presentation Materials
Stock Information
Analyst Coverage
IR Contact
Email Subscription Center
Join Us
Contact Us
>
×
Investor Relations
Information Disclosure
Announcements and Circulars
Financial Reports
Listing Documents
Year
2025
2024
2023
Month
12
11
10
09
08
07
06
05
04
03
02
01
2024-07-24
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M
2024-07-05
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024
2024-07-03
VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH TISLELIZUMAB
2024-06-21
VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-002
2024-06-05
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024
2024-06-03
VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML
2024-05-29
INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY
2024-05-28
List of Directors and their Role and Function
2024-05-28
I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2024; II. APPOINTMENT OF DIRECTOR
2024-05-17
VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A RANDOMIZED, DOUBLEBLIND, CONTROLLED PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE
2024-05-07
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2024
2024-04-29
Proxy Form for the Annual General Meeting to be held on May 28, 2024
2024-04-29
NOTICE OF THE ANNUAL GENERAL MEETING
2024-04-29
(1) 2023 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2023 WORK REPORT OF THE SUPERVISORY COMMITTEE; (3) 2023 ANNUAL REPORT; (4) 2023 FINAL FINANCIAL REPORT AND 2024 FINANCIAL BUDGET REPORT; (5) 2023 PROFIT DISTRIBUTION PLAN; (6) APPOINTMENT OF EXECUTIVE DI
2024-04-26
Annual Report 2023
2024-04-17
VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE PHASE III CLINICAL TRIAL PROTOCOL OF IMM01 (TIMDARPACEPT)
2024-04-08
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024
2024-03-25
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
2024-03-13
DATE OF BOARD MEETING
2024-03-06
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS
总计 91
1
2
3
4
5